These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 2901995

  • 21. Increased platelet activating factor synthesis in experimental colitis after diclofenac and 5-amino-salicylic acid.
    Zijlstra FJ, Van Dijk JP, Wilson JH.
    Eur J Pharmacol; 1993 Nov 02; 249(1):R1-2. PubMed ID: 7506662
    [Abstract] [Full Text] [Related]

  • 22. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
    Kimura I, Kawasaki M, Nagahama S, Matsuda A, Kataoka M, Kokuba Y.
    Arzneimittelforschung; 1998 Nov 02; 48(11):1091-6. PubMed ID: 9850431
    [Abstract] [Full Text] [Related]

  • 23. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
    Tornhamre S, Edenius C, Smedegård G, Sjöquist B, Lindgren JA.
    Eur J Pharmacol; 1989 Oct 10; 169(2-3):225-34. PubMed ID: 2572437
    [Abstract] [Full Text] [Related]

  • 24. Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.
    Roediger W, Schapel G, Lawson M, Radcliffe B, Nance S.
    Biochem Pharmacol; 1986 Jan 15; 35(2):221-5. PubMed ID: 2867767
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of antibody secretion by 5-aminosalicylic acid.
    MacDermott RP, Schloemann SR, Bertovich MJ, Nash GS, Peters M, Stenson WF.
    Gastroenterology; 1989 Feb 15; 96(2 Pt 1):442-8. PubMed ID: 2562949
    [Abstract] [Full Text] [Related]

  • 26. Different therapy for different types of ulcerative colitis in China.
    Jiang XL, Cui HF.
    World J Gastroenterol; 2004 May 15; 10(10):1513-20. PubMed ID: 15133864
    [Abstract] [Full Text] [Related]

  • 27. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis.
    Molin L, Stendahl O.
    Acta Med Scand; 1979 May 15; 206(6):451-7. PubMed ID: 43662
    [Abstract] [Full Text] [Related]

  • 28. Effect of prednisolone on prostaglandin synthesis by rectal mucosa in ulcerative colitis: investigation by laminar flow bioassay and radioimmunoassay.
    Hawkey CJ, Truelove SC.
    Gut; 1981 Mar 15; 22(3):190-3. PubMed ID: 7227851
    [Abstract] [Full Text] [Related]

  • 29. [Localization of salazopyrin in colonic mucosa patients with ulcerative colitis].
    Kitano A, Tabata A, Obayashi M, Nakagawa M, Yasuda K, Fukushima R, Okabe H, Tomobuchi M, Nakamura S, Kashima K.
    Nihon Shokakibyo Gakkai Zasshi; 1993 Feb 15; 90(2):124-33. PubMed ID: 8096555
    [Abstract] [Full Text] [Related]

  • 30. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity.
    Craven PA, Pfanstiel J, Saito R, DeRubertis FR.
    Gastroenterology; 1987 Jun 15; 92(6):1998-2008. PubMed ID: 2883067
    [Abstract] [Full Text] [Related]

  • 31. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
    Naganuma M, Iwao Y, Ogata H, Inoue N, Funakoshi S, Yamamoto S, Nakamura Y, Ishii H, Hibi T.
    Inflamm Bowel Dis; 2001 Aug 15; 7(3):221-5. PubMed ID: 11515848
    [Abstract] [Full Text] [Related]

  • 32. Assessment of the role of platelet-activating factor in an animal model of inflammatory bowel disease.
    Wallace JL, Braquet P, Ibbotson GC, MacNaughton WK, Cirino G.
    J Lipid Mediat; 1989 Aug 15; 1(1):13-23. PubMed ID: 2519884
    [Abstract] [Full Text] [Related]

  • 33. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.
    Daig R, Andus T, Aschenbrenner E, Falk W, Schölmerich J, Gross V.
    Gut; 1996 Feb 15; 38(2):216-22. PubMed ID: 8801200
    [Abstract] [Full Text] [Related]

  • 34. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid.
    Fox CC, Moore WC, Lichtenstein LM.
    Dig Dis Sci; 1991 Feb 15; 36(2):179-84. PubMed ID: 1703070
    [Abstract] [Full Text] [Related]

  • 35. Prostaglandin catabolism and ulcerative colitis: effect of sulphasalazine, 5-aminosalicylic acid and other drugs.
    Pacheco S, Hillier K, Smith CL.
    Braz J Med Biol Res; 1990 Feb 15; 23(12):1323-34. PubMed ID: 1983789
    [Abstract] [Full Text] [Related]

  • 36. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I, Kumamoto T, Matsuda A, Kataoka M, Kokuba Y.
    Arzneimittelforschung; 1998 Oct 15; 48(10):1007-11. PubMed ID: 9825118
    [Abstract] [Full Text] [Related]

  • 37. Eicosanoid production by the mucosa in inflammatory bowel disease after 5-ASA treatment.
    Zijlstra FJ, van Dijk AP, Ouwendijk RJ, van Riemsdijk-Overbeeke IC, Wilson JH.
    Agents Actions; 1993 Oct 15; 38 Spec No():C122-4. PubMed ID: 8317305
    [Abstract] [Full Text] [Related]

  • 38. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I, Kawasaki M, Matsuda A, Kataoka M, Kokurba Y.
    Arzneimittelforschung; 1998 Dec 15; 48(12):1163-7. PubMed ID: 9893931
    [Abstract] [Full Text] [Related]

  • 39. Flufenamic acid inhibition of PGE2 production by rectal mucosa in ulcerative colitis.
    Rachmilewitz D, Ligumsky M, Sharon P, Karmeli F, Zor U.
    Gastroenterology; 1978 Nov 15; 75(5):929-30. PubMed ID: 29819
    [No Abstract] [Full Text] [Related]

  • 40. Concentrations of platelet activating factor in rectal mucosa in patients with ulcerative colitis.
    Almer S, Kald B, Franzén L, Ström M, Tagesson C.
    Eur J Surg; 1996 May 15; 162(5):391-6. PubMed ID: 8781921
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.